F2 Fibrosis in FibroScan (Transient Elastography)
F2 fibrosis in FibroScan represents significant fibrosis with a liver stiffness measurement value greater than 7.0 kPa, indicating moderate liver damage that warrants consideration for antiviral therapy in chronic hepatitis B patients. 1, 2
Definition and Diagnostic Criteria
- F2 fibrosis is classified as "significant fibrosis" in the METAVIR scoring system, representing an intermediate stage of liver fibrosis between mild fibrosis (F0-F1) and advanced fibrosis (F3-F4) 2
- According to the 2024 WHO guidelines, F2 fibrosis on FibroScan is diagnosed when liver stiffness measurements exceed 7.0 kPa 1
- This cutoff value was established based on systematic reviews and meta-analyses to provide actionable thresholds for clinical use 1
- F2 fibrosis indicates that fibrosis has extended beyond the portal tracts with the formation of some fibrous septa, but without architectural distortion 2, 3
Clinical Significance
- The identification of F2 fibrosis is clinically important as it represents a threshold for treatment decisions in chronic liver diseases, particularly viral hepatitis 1
- According to the 2024 WHO guidelines, treatment is now recommended for all adults and adolescents with chronic hepatitis B who have evidence of significant fibrosis (≥F2) regardless of HBV DNA or ALT concentrations 1
- Early identification of F2 fibrosis allows for intervention before progression to more advanced stages that are associated with increased morbidity and mortality 2, 4
- F2 fibrosis is associated with a higher risk of liver-related complications compared to F0-F1, but lower risk than F3-F4 5, 4
Diagnostic Performance
- FibroScan has a sensitivity of 75.1% and specificity of 79.3% for detecting significant fibrosis (F2-F4) using cutoffs between 6.0-8.0 kPa 2
- The WHO meta-analysis showed that using a FibroScan cutoff of >7.0 kPa for ≥F2 fibrosis provides optimal diagnostic accuracy 1
- When using this cutoff in patients with a 25% baseline prevalence of significant fibrosis, approximately 26.2% of treated patients may not have significant fibrosis (false positives), while only 6.8% of patients with significant fibrosis would be missed (false negatives) 1
- The diagnostic accuracy of FibroScan for F2 fibrosis is generally lower than for cirrhosis (F4), which has more distinct elastographic properties 2, 6
Diagnostic Algorithm for F2 Fibrosis
- Initial assessment should begin with blood-based biomarkers like FIB-4 or APRI as screening tools 2, 7
- If FIB-4 <1.45 or APRI <0.5, there is a low probability of F2+ fibrosis 2, 8
- If FIB-4 >1.45 or APRI >0.5, proceed to FibroScan 2, 5
- FibroScan values between 7.0-9.5 kPa suggest F2 fibrosis 1, 2
- Values >9.5 kPa suggest F3 fibrosis, while values >12.5 kPa indicate cirrhosis (F4) 1, 5
Technical Considerations and Limitations
- For reliable FibroScan results, at least 10 successful measurements with a success rate of ≥60% and an interquartile range <30% of the median value are required 5, 9
- FibroScan has limitations in patients with ascites, severe obesity, narrow intercostal spaces, acute hepatitis, or extrahepatic biliary tract obstruction 5, 4
- Acute inflammation can falsely elevate elastography readings, potentially leading to overestimation of fibrosis stage 2, 9
- Different cutoffs may apply depending on the underlying liver disease (viral hepatitis vs. NAFLD/MASH) 2, 4
Management Implications
- Patients with F2 fibrosis require more aggressive management than those with F0-F1 fibrosis 5, 4
- For chronic hepatitis B patients, the WHO now recommends antiviral therapy for all patients with ≥F2 fibrosis 1
- Regular monitoring with repeat FibroScan is recommended, typically every 1-2 years for patients with F2 fibrosis 5
- Sequential testing using blood-based markers followed by FibroScan improves diagnostic accuracy compared to using either test alone 2, 5